Search research articles
Contact Us
Filters
Showing results (161-170 of 260) with videos related to
Page
of 26
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 6, 2023
Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers
Timothy P DiPeri, Kurt W Evans, Maria Gabriela Raso, et al.
British Journal of Haematology
|
March 23, 2023
Outcomes of patients with therapy-related myeloid neoplasms after treatment with poly(ADP-ribose) polymerase proteins inhibitors for solid tumours
Emmanuel Almanza-Huante, Alex Bataller, Samuel Urrutia, et al.
JCO Precision Oncology
|
February 2, 2022
Clinical and Molecular Characterization of <i>POLE</i> Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers
Benjamin Garmezy, Jinesh Gheeya, Heather Y Lin, et al.
Oncogene
|
July 26, 2023
A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-∆11q splice variant
Stephen J Pettitt, Nan Shao, Diana Zatreanu, et al.
Biorxiv : the Preprint Server for Biology
|
April 27, 2026
ARID1A deficiency unleashes centromeric RNA transcription to drive chromosomal instability and boosts PKMYT1 inhibitor efficacy via RNA sensing
Chengguo Li, Xueqian Cheng, Weizhen Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2017
A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors
Kurt W Evans, Erkan Yuca, Argun Akcakanat, et al.
Investigational New Drugs
|
September 24, 2021
Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study
Rony Dev, Linda L Zhong, Abdulrazzak Zarifa, et al.
Cancer
|
March 17, 2023
Clinical implications of tumor-based next-generation sequencing in high-grade epithelial ovarian cancer
Katherine I Foster, Kenna R M Shaw, Jeff Jin, et al.
Molecular Cancer Therapeutics
|
April 29, 2010
AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growth
Kyla M Grimshaw, Lisa-Jane K Hunter, Timothy A Yap, et al.
Oncotarget
|
April 29, 2017
Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer
Saeed Rafii, Charlie Gourley, Rajiv Kumar, et al.
Page
of 26
Search research articles
Search
Showing results (161-170 of 260) with videos related to
Sort By:
Page
of 26
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 6, 2023
Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers
Timothy P DiPeri, Kurt W Evans, Maria Gabriela Raso, et al.
British Journal of Haematology
|
March 23, 2023
Outcomes of patients with therapy-related myeloid neoplasms after treatment with poly(ADP-ribose) polymerase proteins inhibitors for solid tumours
Emmanuel Almanza-Huante, Alex Bataller, Samuel Urrutia, et al.
JCO Precision Oncology
|
February 2, 2022
Clinical and Molecular Characterization of <i>POLE</i> Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers
Benjamin Garmezy, Jinesh Gheeya, Heather Y Lin, et al.
Oncogene
|
July 26, 2023
A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-∆11q splice variant
Stephen J Pettitt, Nan Shao, Diana Zatreanu, et al.
Biorxiv : the Preprint Server for Biology
|
April 27, 2026
ARID1A deficiency unleashes centromeric RNA transcription to drive chromosomal instability and boosts PKMYT1 inhibitor efficacy via RNA sensing
Chengguo Li, Xueqian Cheng, Weizhen Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2017
A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors
Kurt W Evans, Erkan Yuca, Argun Akcakanat, et al.
Investigational New Drugs
|
September 24, 2021
Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study
Rony Dev, Linda L Zhong, Abdulrazzak Zarifa, et al.
Cancer
|
March 17, 2023
Clinical implications of tumor-based next-generation sequencing in high-grade epithelial ovarian cancer
Katherine I Foster, Kenna R M Shaw, Jeff Jin, et al.
Molecular Cancer Therapeutics
|
April 29, 2010
AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growth
Kyla M Grimshaw, Lisa-Jane K Hunter, Timothy A Yap, et al.
Oncotarget
|
April 29, 2017
Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer
Saeed Rafii, Charlie Gourley, Rajiv Kumar, et al.
Page
of 26